Quince Therapeutics (QNCX) Cash from Financing Activities (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Cash from Financing Activities of $9.4 million for Q1 2026, up 10754.02% year-over-year from N/an in Q1 2025, and up 364.26% quarter-over-quarter from $2.0 million in Q4 2025.
Quince Therapeutics (QNCX) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Quince Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $9.4 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 10754.02% year-over-year to $9.4 million; the TTM figure through Mar 2026 stood at $27.3 million (up 658.94% YoY), while the FY2025 annual figure was $17.9 million, up 475.06% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $9.4 million, up from $2.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $14.4 million in Q2 2025, with the low at -$5.0 million in Q3 2024.
- The 5-year median for Cash from Financing Activities is $72000.0 (2023), against an average of $1.5 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities plunged 50100.0% in 2024, then soared 41077.14% in 2025.
- Quince Therapeutics' Cash from Financing Activities stood at -$18000.0 in 2022, then surged by 416.67% to $57000.0 in 2023, then tumbled by 8871.93% to -$5.0 million in 2024, then jumped by 140.68% to $2.0 million in 2025, then soared by 364.26% to $9.4 million in 2026.
- Business Quant data shows QNCX's Cash from Financing Activities at $9.4 million in Q1 2026, $2.0 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | 108.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.44 Mn |
| Mar 31, 2026 | 9.44 Mn |
| Dec 31, 2025 | 2.03 Mn |
| Dec 31, 2025 | 2.03 Mn |
| Sep 30, 2025 | 1.38 Mn |
| Sep 30, 2025 | 1.38 Mn |
| Jun 30, 2025 | 14.41 Mn |
| Jun 30, 2025 | 14.41 Mn |
| Mar 31, 2025 | 87,000.00 |
| Mar 31, 2025 | 87,000.00 |
| Sep 30, 2024 | -5.00 Mn |
| Sep 30, 2024 | -5.00 Mn |
| Jun 30, 2024 | 35,000.00 |
| Jun 30, 2024 | 35,000.00 |
| Mar 31, 2024 | 190,000.00 |
| Mar 31, 2024 | 190,000.00 |
| Dec 31, 2023 | 57,000.00 |
| Dec 31, 2023 | 57,000.00 |
| Sep 30, 2023 | 10,000.00 |
| Sep 30, 2023 | 10,000.00 |